ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, AND METHOD FOR PREVENTING OR TREATING DISEASES BY USING ROR1-POSITIVE MESENCHYMAL STEM CELLS

WIPO Patent Application WO/2017/038784

A1

The purpose of the present invention is to provide: new mesenchymal stem cells having excellent therapeutic effect on various diseases, a new pharmaceutical composition containing the mesenchymal stem cells, and a method for preparing the same. The present invention is ROR1-positive mesenchymal stem cells. Preferably, the ROR1-positive mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive, and are derived from an umbilical cord or fat.

JP2007238559	IMMATURE DENDRITIC CELL-ACTIVATING AGENT AND USE THEREOF
WO/2014/153089	CD14+ CELL COMPOSITIONS AND METHODS OF USING SAME
JP2020517259	Immune cells expressing engineered antigen receptors

IKEYAMA YOSHIFUMI (JP)
NISHIDA HIROYUKI (JP)
TSUDA TOMOHIRO (JP)
UNO EIKO (JP)
YUMOTO MASAYO (JP)
SUDA KAZUMA (JP)
YOSHINO MIHOKO (JP)
NGO XUAN TRUNG (JP)

PCT/JP2016/075251

March 09, 2017

August 29, 2016

Click for automatic bibliography generation  

ROHTO PHARMA (JP)

A61K35/28; C12N5/0775; A61P1/00; A61P1/16; A61P1/18; A61P3/00; A61P9/00; A61P19/00; A61P35/00; A61P43/00

WO2014031174A1

2014-02-27

HUDECEK M. ET AL.: "The B- cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", BLOOD, vol. 116, no. 22, 2010, pages 4532 - 4541, XP055034816
ZHANG S. ET AL.: "Ovarian cancer stem cells express ROR1, which can be targeted for anti- cancer-stem- cell therapy", PROC.NATL.ACAD.SCI. USA, vol. 111, no. 48, 2014, pages 17266 - 17271, XP055186204

TSUKUNI & ASSOCIATES et al. (JP)

View/Download PDF      PDF Help

Previous Patent: SPOUT-EQUIPPED CONTAINER AND REFILLING METHOD

Next Patent: GASKET